Ignite Creation Date:
2024-05-06 @ 4:00 PM
Last Modification Date:
2024-10-26 @ 2:01 PM
Study NCT ID:
NCT04836832
Status:
WITHDRAWN
Last Update Posted:
2022-06-07
First Post:
2021-03-09
Brief Title:
Acalabrutinib and Duvelisib for the Treatment of RelapsedRefractory Indolent Non-Hodgkin Lymphoma
Sponsor:
Narendranath Epperla
Organization:
Ohio State University Comprehensive Cancer Center
Organization Data
Organization:
Ohio State University Comprehensive Cancer Center
Class:
OTHER
Study ID:
OSU-20179
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Narendranath Epperla
Lead Sponsor Class:
OTHER
Responsible Party:
Narendranath Epperla
Responsible Party Title:
Principal Investigator
Responsible Party Type:
SPONSOR_INVESTIGATOR
Responsible Party Affiliation:
Ohio State University Comprehensive Cancer Center
Old Name:
None
Old Organization:
None